Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASN51 Safety, PK, and PD in Healthy Volunteers and Alzheimer's Disease
NCT04759365Phase 1Terminated
- Sponsor
- Asceneuron SA
- Start
- Jun 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing ASN51 with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events up to 38 days. Started Jun 2021; status: terminated.
02
Drugs
ASN51
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04759365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04759365.